10/11/2026
One year after launch, 68% of patients are covered for new therapies, and 91% of that coverage carries no restrictive prior authorization conditions beyond the product label.
This has held broadly steady over the last decade, but the annual trend for 2024 and 2025 is drifting downward, and the direction matters.
Payers are becoming more active. Utilization management is tightening. The Inflation Reduction Act is shifting the pricing dynamic. These are not temporary pressures.
Therapy area mix drives significant variation, too. As large pharma portfolios keep shifting into cardiometabolic and neurology, the overall access benchmark will face further pressure.
The takeaway from the P3i is direct: market access has become a binding constraint on return on investment. Strong development and launch performance are no longer enough without an early, therapy-specific access strategy.
Approval is a checkpoint. Access is the outcome that matters.
Explore the full analysis from Daniel Chancellor, VP, Thought Leadership at Norstella.
Unlock smarter pipeline-to-patient decisions by accessing the report: https://vist.ly/5mxe6
